Literature DB >> 10490816

The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.

I Bongarzone1, E Vigano, L Alberti, P Mondellini, M Uggeri, B Pasini, M G Borrello, M A Pierotti.   

Abstract

Mutations of the RET gene, encoding a receptor tyrosine kinase, have been associated with the inherited cancer syndromes MEN 2A and MEN 2B. They have also further been associated with both familial and sporadic medullary thyroid carcinomas. Missense mutations affecting cysteine residues within the extracellular domain of the receptor causes constitutive tyrosine kinase activation through the formation of disulfide-bonded homodimers. We have recently reported that a somatic 6 bp in-frame deletion, originally coding for Glu632-Leu633, potently activates the RET gene. This activation is increased with respect to the frequent MEN 2A-associated missense mutation Cys634Arg. This finding specifically correlated to the clinic behavior of the corresponding tumor, which was characterized by an unusually aggressive progression with both multiple and recurrent metastases. By examining the possibility that this deletion acts in a manner similar to cysteine substitution, we have analysed the molecular mechanism by which this oncogenic activation occurs. Phosphorylated dimers of the deleted Ret receptor were detected in immunoprecipitates separated under non-reducing conditions. Like other Cys point mutations, this 6 bp deletion affecting two amino acid residues between two adjacent Cys, is capable of activating the transforming ability of Ret by promoting receptor dimerization. These results suggest that alteration to cysteine residue position or pairing is capable of inducing ligand independent dimerization. Furthermore, we present data demonstrating that the processing and sorting of the Ret membrane receptor to the cell surface is affected by mutation type.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10490816     DOI: 10.1038/sj.onc.1202848

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

1.  The sensitivity of activated Cys Ret mutants to glial cell line-derived neurotrophic factor is mandatory to rescue neuroectodermic cells from apoptosis.

Authors:  B Mograbi; R Bocciardi; I Bourget; T Juhel; D Farahi-Far; G Romeo; I Ceccherini; B Rossi
Journal:  Mol Cell Biol       Date:  2001-10       Impact factor: 4.272

2.  Pediatric, Adolescent, and Young Adult Thyroid Carcinoma Harbors Frequent and Diverse Targetable Genomic Alterations, Including Kinase Fusions.

Authors:  Pierre Vanden Borre; Alexa B Schrock; Peter M Anderson; John C Morris; Andreas M Heilmann; Oliver Holmes; Kai Wang; Adrienne Johnson; Steven G Waguespack; Sai-Hong Ignatius Ou; Saad Khan; Kar-Ming Fung; Philip J Stephens; Rachel L Erlich; Vincent A Miller; Jeffrey S Ross; Siraj M Ali
Journal:  Oncologist       Date:  2017-02-16

3.  Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers.

Authors:  Taccaliti A; Silvetti F; Palmonella G; Boscaro M
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

4.  A PCR-mutagenesis strategy for rapid detection of mutations in codon 634 of the ret proto-oncogene related to MEN 2A.

Authors:  María Roqué; Eduardo Pusiol; Héctor Perinetti; Clara Pott Godoy; Luis S Mayorga
Journal:  BMC Med Genet       Date:  2002-05-21       Impact factor: 2.103

5.  Genetic and Epigenetic of Medullary Thyroid Cancer

Authors:  Fatemeh Khatami; Seyed Mohammad Tavangar
Journal:  Iran Biomed J       Date:  2017-11-11

6.  Results and Clinical Interpretation of Germline RET Analysis in a Series of Patients with Medullary Thyroid Carcinoma: The Challenge of the Variants of Uncertain Significance.

Authors:  Giovanni Innella; Cesare Rossi; Maria Romagnoli; Andrea Repaci; Davide Bianchi; Maria Elena Cantarini; Davide Martorana; Lea Godino; Andrea Pession; Antonio Percesepe; Uberto Pagotto; Daniela Turchetti
Journal:  Cancers (Basel)       Date:  2020-11-05       Impact factor: 6.639

Review 7.  Precision oncology for RET-related tumors.

Authors:  Antonella Verrienti; Giorgio Grani; Marialuisa Sponziello; Valeria Pecce; Giuseppe Damante; Cosimo Durante; Diego Russo; Sebastiano Filetti
Journal:  Front Oncol       Date:  2022-08-24       Impact factor: 5.738

8.  Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.

Authors:  Andreas M Heilmann; Vivek Subbiah; Kai Wang; James X Sun; Julia A Elvin; Juliann Chmielecki; Steven I Sherman; Ravi Murthy; Naifa L Busaidy; Ishwaria Subbiah; Roman Yelensky; Chaitali Nangia; Jo-Anne Vergilio; Saad A Khan; Rachel L Erlich; Doron Lipson; Jeffrey S Ross; Vincent A Miller; Manisha H Shah; Siraj M Ali; Philip J Stephens
Journal:  Oncology       Date:  2016-05-21       Impact factor: 2.935

9.  Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4.

Authors:  Vijay G Bhoj; Lucy Li; Kalpana Parvathaneni; Zheng Zhang; Stephen Kacir; Dimitrios Arhontoulis; Kenneth Zhou; Bevin McGettigan-Croce; Selene Nunez-Cruz; Gayathri Gulendran; Alina C Boesteanu; Laura Johnson; Michael D Feldman; Enrico Radaelli; Keith Mansfield; MacLean Nasrallah; Rebecca S Goydel; Haiyong Peng; Christoph Rader; Michael C Milone; Don L Siegel
Journal:  Mol Ther Oncolytics       Date:  2021-01-26       Impact factor: 7.200

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.